Shuttle Pharmaceuticals Inc (SHPH) - Total Liabilities
Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) has total liabilities worth $8.22 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore SHPH cash flow metrics to assess how effectively this company generates cash.
Shuttle Pharmaceuticals Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Shuttle Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check SHPH financial resilience to evaluate the company's liquid asset resilience ratio.
Shuttle Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Shuttle Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aeon Metals Ltd
AU:AML
|
Australia | AU$40.24 Million |
|
Trugolf Inc
NASDAQ:TRUG
|
USA | $16.73 Million |
|
Marston’s PLC
LSE:MARS
|
UK | GBX1.53 Billion |
|
Property Franchise Group PLC
LSE:TPFG
|
UK | GBX51.32 Million |
|
KD Corporation
KQ:044180
|
Korea | ₩277.57 Billion |
|
iSpecimen Inc
NASDAQ:ISPC
|
USA | $6.44 Million |
|
Octopus Renewables Infra Trust
LSE:ORIT
|
UK | GBX1.50 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Shuttle Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SHPH market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shuttle Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shuttle Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of Shuttle Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.22 Million | +357.48% |
| 2024-12-31 | $1.80 Million | -5.21% |
| 2023-12-31 | $1.90 Million | +94.32% |
| 2022-12-31 | $975.68K | -57.20% |
| 2021-12-31 | $2.28 Million | +2.03% |
| 2020-12-31 | $2.23 Million | +276.27% |
| 2018-12-31 | $593.82K | +46.39% |
| 2017-12-31 | $405.65K | -- |
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clini… Read more